Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

FHS
July 15, 2024
4:30 am

Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.

PAION AG cancelled guidance for financial year 2023 – Biotech Investments

PAION AG / Key word(s): Change in Forecast PAION AG cancelled guidance for financial year 2023 24-Nov-2023 / 13:46 CET/CEST Disclosure of an inside information

November 25, 2023

DexCare Raises $75M to Accelerate Care Access Platform

What You Should Know: DexCare, Inc., a Seattle-based patient demand and care access platform raises $75M in Series C funding led by ICONIQ Growth with

June 21, 2023

UnitedHealth’s Andrew Witty gets no pity in Congress

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in

May 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.